Strategies for successful commercial-readiness in gene therapy

Insights from Orchard’s HSC gene therapy supply chain development

Advancements in cell and gene therapy

2020 year-in-review

Maintaining business continuity during COVID-19

Lessons learned will have positive impacts beyond the pandemic

Scaling cell therapy supply chains during a pandemic

Achieving donor pool sustainability and cell therapy supply chain success

5 Qualities to Seek in Your Cell Therapy Supply Chain Vendor

Considerations to help lower your cell or gene therapy logistics risk

Overcoming autologous cell therapy logistics challenges in the age of COVID-19

Experienced team for managed logistics is key

How COVID-19 is changing the production of cell therapies

Implementation of contingency plans allows for continued progress in therapy development

Managing donor collections during the COVID-19 pandemic

Why a diverse apheresis center network is critical to business continuity

Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)

Why established systems and relationships matter